The observed effect of midazolam on anxiety is equivocal in part because previous studies have not ruled out pre-treatment differences in anxiety scores between patients who received midazolam and those who did not (controls). This study re-examines the anxiolytic effect of premedication with intramuscular mida70lam using a sample size calculated to be of sufficient size to rule out population differences as a variable affecting treatment results. In the midazolam group (n = 49) anxiety scores were determined prior to administration ofmidazolam 0.07 mg/kg intramuscularly, and again 60 minutes later. In the control group (n = 47) anxiety scores were determined prior to intramuscular injection of a similar volume of matching placebo (midazolam vehicle), and again 60 minutes later. No differences in anxiety scores between groups either before treatments or 60 minutes after treatments were observed. Within both groups, anxiety scores at 60 minutes were no different from pre-treatment scores. In this study midazolam did not produce a statistically significant decrease in pre-operative anxiety scores at 60 minutes following intramuscular administration.
minutes after administration.! However, data were not treated by statistical analysis and no control group was employed. Thus the reduction in anxiety scores may have been either not statistically significant, or not different from a placebo effect. Four other studies evaluated midazolam using a doubleblind, placebo-controlled parallel-group design. 2 -5 Two reported a significantly greater decrease in anxiety scores at 60 minutes following midazolam than in controls,2,3 while the other two reported no decrease in anxiety scores at 60 minutes with midazolam. 4 ,5 In all four studies the results may have been affected by differences in anxiety levels between groups prior to administration of midazolam. In two of the reports 2 ,3 the number of patients studied provides inadequate statistical power (33070 -59070, see Appendix) to rule out differences in anxiety levels between groups prior to midazolam. In the third study pretreatment differences in anxiety scores between the midazolam group and controls were even greater, and the data were not treated by statistical analysis. 4 In the fourth study initial anxiety scores were not tabulated. 5 We sought to examine the anxiolytic properties of midazolam using an experimental design that would minimise the influence of pre-treatment differences in anxiety levels on the results. Accordingly, we calculated the number of patients that would have to be studied (n = 47 per group, see Appendix) in order to reduce to an acceptable level (0.15) the probability of overlooking initial differences in anxiety scores. We then undertook the present study to examine the effect of intramuscular midazolam on anxiety scores at 60 minutes using a double-blind, placebo-controlled parallel-group design.
MATERIALS AND METHODS
Ninety-six adult patients scheduled for elective surgery comprised the study population for this multi-institutional investigation. Written consent was obtained from all patients. Approval for the study was obtained from the Human Subjects Committee at each participating institution. All aspects of patient selection and study design were strictly adhered to and were similar at each location. The initial criteria used to select patients were: males or nonpregnant females; ages 18-65; of ASA physical status I and 11; undergoing noncardiac, non-neurological surgery; with no known sensitivity to benzodiazapines. Patients receiving tranquilisers, sedatives, hypnotics, antihistamines, or narcotics within 72 hours prior to surgery were excluded.
Patients who satisfied these intial criteria for consideration for participation were asked to complete the Anxiety Visual Analog Test (A V AT). The AV AT is a visual analogue quantitative measure of anxiety.2 To determine the A VAT score, patients are given a sheet of paper with a line 100 mm in length and asked to rate their anxiety along the line (from 0 to 100 mm). Only patients with a subjective anxiety score of ~50OJo on the A V AT on the night before surgery were included in this study. Patients with A V AT scores <50070 on the night before surgery demonstrate little change in anxiety scores with proven anxiolytic treatments, and therefore are not suitable to evaluate a treatment that is being examined for relief of anxiety. Patients satisfying all inclusion criteria were randomised into either the midazolam group or the control group. Patient selection continued until both groups contained at least 47 patients.
Assessment of relief from anxiety was determined from the change in A VAT scores obtained on the day of surgery. The baseline A VAT score was obtained just prior to premedication. The experimental A VAT score was obtained at 60 minutes following premedication. The premedication was administered 60-90 minutes before surgery according to a random design. Patients in the midazolam group received midazolam 0.07 mg/kg, while patients in the control group received a similar volume of matching placebo (midazolam vehicle). The medications were injected from blinded, single-dose ampoules into the vastus lateralis muscle using a 4-cm 22-gauge needle.
Sedation, change in heart rate and systemic blood pressure, and incidences of apnoea, dysphoria, and cutaneous reactions at the site of administration also were examined. Systemic blood pressure was determined by auscultation, heart rate was determined by palpation, and respiratory rate was observed. These variables were measured before the injection of premedication and thereafter every fifteen minutes during the premedication phase. Any discomfort at the time of intramuscular lllJection was noted. Immediately postoperatively and at 24 and 48 hours later the intramuscular injection site was examined for pain, swelling, redness and induration.
Midazolam and control groups were compared for relief of anxiety and for the other aforementioned variables. For relief of anxiety, cardiovascular variables and level of sedation, the trial was considered to be a two treatment, parallel group design. Analysis of covariance was performed on A V A T scores, systemic blood pressure, heart rate, and the observed sedation level with the baseline value for each variable as the covariate. Fisher's Exact test was used to compare proportions of patients for quality of sedation and incidences of apnoea, dysphoria, and cutaneous reactions. A P value <0.05 was considered significant.
RESULTS
As a result of the random nature of patient assignment, 49 patients were entered into the midazolam group and 47 patients were entered into the control group. There were no significant differences between the midazolam and control groups regarding patient characteristics or baseline systemic variables (Table 1) . Baseline A VAT scores were not significantly different between the midazolam and control groups ( Table 2 ). Sixty minutes after medication, A V AT scores did not change from baseline values within groups and also were not different between groups.
Sedation was observed at all post-medication observation periods following midazolam but not in controls (Table 3 ). Systemic 1:Jlood pressure and heart rate remained stable in both groups following medication (not tabulated), and no incidences of apnoea or dysphoria were observed. With midazolam incidences of discomfort with intramuscular injection, or cutaneous reaction immediately postoperatively, or at 24 or 48 hours (3070) were not significantly different from that with intramusular injection of midazolam vehicle (3070 ).
DISCUSSION
The present results suggest that intramuscular midazolam 0.07 mg/kg does not produce a statistically significant reduction in Systolic blood pressure, mmHg 121 (12) 123 (13) Diastolic blood pressure, mmHg 71 (9) 73 (10) Heart rate, beats/min 74 (13) 76 (14) anxiety scores 60 minutes after administration. However, care should be taken not to generalise this result to the conclusion that midazolam has no effect on anxiety. First, this study employed a sample size large enough to reduce to an acceptable level (0.15) the possibility of a type 11 statistical error regarding pre-treatment anxiety scores. Had a larger sample size been chosen, the difference in post-treatment anxiety scores between patients receiving midazolam and controls may have achieved statistical significance. Second, failure to reach statistical significance does not mean that no difference existed between the midazolam group and controls. The level at which a reduction in A V A T score becomes clinically relevant is not known. It may be that a reduction of A V AT score to 5.6 below control or to 12.8 below baseline is clinically important, though not statistically significant. Should a future study define the reduction in A VAT score that is clinically significant, such information could be used to select the sample sizes for subsequent studies of anxiolytic treatments. Regarding other patient responses to midazolam, the responses of our population samples were similar to those previously reported by others. Our observation that patients were drowsy 15 minutes after intramuscular administration agrees with a previous clinical study reporting initial drug effects at 3-10 minutes after intramuscular midazolam (Midazolam Investigational Drug Brochure, Hoffman La Roche, Nutley, New Jersey). Our observation that patients were drowsy for up to 60 minutes after intramuscular administration of midazolam agrees with the duration of sedation (60-90 minutes) observed in previous clinical studies where midazolam was compared with hydroxyzine. 2 . s Onset of sedative action at 15 minutes with continued sedation for up to 60 minutes after administration also is consistent with previous pharmacokinetic studies with midazolam. Following intramuscular administration, midazolam is rapidly absorbed and reaches peak blood levels after 30 minutes. 7 In the present study, the sedative action of midazolam occurred in the absence of a statistically significant change in anxiety scores. This result reflects our clinical observation that patients often appeared drowsy at the time of the 60 min AV AT test yet still evaluated themselves as anxious. That a perception of anxiety should continue despite midazolaminduced sedation is consistent with previous observations that natural drowsiness or sleep does not abolish underlying feelings of anxiety.8 Persistent feelings of anxiety despite sedation induced by a number of central nervous system depressants also has been previously reported. 9, 10 The low incidence of tissue reaction to intramuscular midazolam (3070) is consistent with that reported in previous studies (0-5 %). [2] [3] [4] [5] This clinical observation is supported by histopathologic studies. 11 By comparison, Dundee et al. reported the incidence of pain with intramuscular injection of diazepam to be 12%, and that with intramuscular lorazepam to be 24%. 12 Absence of significant change in heart rate or blood pressure with intramuscular midazolam is consistent with that reported in a previous study of intramuscular midazolam (0.07 mg/kg) for premedication. 3 Even when larger doses of midazolam (0.2-0.3 mg/kg) are administered intravenously for induction of anaesthesia, minimal haemodynamic In summary, our results suggest that midazolam does not produce a statistically significant reduction of anxiety scores at 60 minutes following intramuscular administration. Our findings also reaffirm the need to choose adequate sample sizes in order to obtain reliable data in clinical studies.
ApPENDIX

Power
The power of a test gives the probability of finding a significant difference when real differences exist between the true mean (Ji) of a study group and the null mean (IiO>. If the power is too low there is little chance of finding a significant difference and the results will appear nonsignificant, even though a real difference exists. An inadequate sample size is almost always the cause of low power.
Power (1-(3) can be calculated using the equation: The power of both studies is well below the ;;>80% probability recommended for biological statistics. 6 In the other two studies that examined the effect of midazo1am on anxiety scores,4,5 lack of data prohibits calculation of statistical power. Because in all four studies a difference in the control and midazolam groups prior to treatment cannot be ruled out, the difference in anxiety scores posttreatment could have been caused by sample (patient) di fferences rather than by the treatments,
Selecting a sample size
If it is not known whether the alternative mean (!l\) is greater or less than the null mean (!lo), then a two-sided test is appropriate and the corresponding sample size needed to conduct a study with significance level = a and power = 1-(3 is given by the equation:
Anaesthesia and Intensive Care. Vo!. 14, No. 2, May, 1986 where a = the standard deviation of a random varible, and Z = the percentile of a normal distribution, For purposes of the present study, a value of 22,2 was used for a (the average of previously reported values: 24,325,6,2 and 17 4 ), a value of 9,7 was used for iJo-iJ\ (the average of previously reported values: 16,54,3 and 92), the significance level was 0,05, and the power was 0,85, Z values were taken from a standard table of normal distribution function,6 Thus: 491 (1.04 + I. 96)2 n= =47 94 Note that this calculation for selecting the sample size necessary to reduce to an acceptable level (0,15) the probability of overlooking pre-treatment differences in anxiety scores is based on previously reported values, There are no previous reports to justify that a 9,7 reduction in AV A T score is clinically useful.
